Startups channel feed

Ex­clu­sive: Al­lay reach­es $57.5M Se­ries D mile­stone for post-sur­gi­cal pain drug

Last month
Financing

Ex­clu­sive: Tech VC Am­pli­fy rais­es $200M for first biotech fund, hires El­liot Her­sh­berg as new part­ner

Last month
Financing

Dig­i­tal health start­up Vir­ta stakes fees on curb­ing GLP-1 pre­scrip­tions

Last month
Health Tech

Ex­clu­sive: Cin­Dome gets an­oth­er $40M to ad­vance gas­tro­pare­sis drug

Last month
Financing

Canid rais­es $10M to man­age vac­cines for pe­di­a­tri­cians

Last month
Financing
Health Tech

Ko­re­an start­up Curo­gen seeks glob­al ex­pan­sion, new fund­ing to back au­toim­mune drugs

Last month
Financing

DNA gi­ant Il­lu­mi­na spawned an ecosys­tem of com­peti­tors and cus­tomers

Last month
In Focus
Diagnostics

Ex­clu­sive: Move­ment dis­or­der biotech Vi­ma steps on­to scene with $60M

Last month
Financing

In­sur­ance start­up De­vot­ed Health cuts 5% of work­ers in small lay­off

Last month
People
Health Tech

Weeks af­ter TIG­IT fail, iTeos de­cides to wind down

Last month
People

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

Last month
Financing

Bio­gen taps City Ther­a­peu­tics in RNAi deal worth up to $1B

Last month
Deals
Pharma

In­vestors pump $130M in­to pro­tein de­grad­er start­up Gly­co­Era

Last month
Financing

TCG's R&D ven­ture team makes a T cell en­gager deal with Shang­hai biotech

Last month
Deals
China

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

Last month
In Focus

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

Last month
Deals

Re­pro­duc­tive health biotech snags $65M to de­vel­op for­mer No­var­tis and Mer­ck KGaA drugs

Last month
Financing

UK biotech Ju­ve­nes­cence tar­gets $150M+ for 'healthy lifes­pan' drug can­di­dates

Last month
Financing

Ex­clu­sive: Weight loss start­up Cal­i­brate swaps CEOs in lat­est lead­er­ship shake­up

Last month
People
Health Tech

Retro Bio­sciences inks blood dis­or­der deal as Sam Alt­man-backed biotech seeks $1B in funds

Last month
Deals
Cell/Gene Tx

Ex­clu­sive: Cell­Cen­tric col­lects $120M to treat mul­ti­ple myelo­ma with a cap­sule

Last month
Financing

Ap­n­imed posts first set of Phase 3 sleep ap­nea re­sults, aims for ap­proval fil­ing in 2026

Last month
R&D

It's been three months with­out a biotech IPO

Last month
Financing

Eli Lil­ly turns to South Ko­re­an RNA edit­ing biotech for hear­ing loss in deal worth $1.3B

Last month
Deals
Cell/Gene Tx
First page Previous page 12345 Next page Last page
A service from the Financial Times